Inhibition of fibroblast proliferation

Inhibition of fibroblast proliferation refers to the biological or pharmacological suppression of fibroblast cell division, a process central to the pathogenesis of various fibrotic diseases (PMID: 22122811). Fibroblasts are the primary cells responsible for synthesizing the extracellular matrix and collagen, playing a critical role in normal tissue repair and wound healing. However, in chronic inflammatory conditions, these cells can become hyper-proliferative, leading to excessive scarring and organ dysfunction, such as in idiopathic pulmonary fibrosis or liver cirrhosis (PMID: 24834445). This process is not a single molecular target but a therapeutic goal achieved by drugs like nintedanib, which inhibits multiple tyrosine kinase receptors (PDGFR, FGFR, VEGFR), and pirfenidone, which modulates TGF-beta signaling (PMID: 25144637, PMID: 26338148). While effective at slowing the progression of fibrosis, systemic inhibition of fibroblast activity can lead to significant safety concerns, including delayed wound healing and mucosal damage. Consequently, the term describes a phenotypic effect resulting from the modulation of various upstream molecular targets.

Other names

Fibroblast growth inhibitionAnti-fibrotic effectSuppression of fibroblast proliferationFibroblast cytostasis

This is a biological process or phenotypic outcome rather than a single molecular target. Drugs achieve this effect by inhibiting specific signaling pathways, such as those mediated by Transforming Growth Factor-beta (TGF-beta), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF), which are the primary drivers of fibroblast activation and mitotic division (PMID: 25144637, PMID: 26338148).